Ophthalmic Innovation
Advancing the industry’s most comprehensive ophthalmic surgical and pharmaceutical pipeline
At Glaukos, we are dedicated to addressing the greatest unmet needs of the global ophthalmic market, for physicians and for patients. That’s why we’ve spent more than a decade re-investing in R&D and clinical trial programs to develop and advance a deep pipeline of novel therapies currently being evaluated in FDA clinical trials, while leading the industry in clinical support and patient education resources. And it’s why we’re seeking to leverage our platform technologies to build an unrivaled portfolio of next-generation surgical and pharmaceutical therapies in glaucoma, corneal health, and retinal disease.
We’ve achieved many firsts in clinical studies and over the past several years, Glaukos has reinvested approximately 30% of all sales back into research and development activities – all to relentlessly advance our goal of creating and delivering transformative therapies for patients struggling with eye diseases and the skilled surgeons dedicated to their healing.
Glaukos’ Commitment to R&D
Pricing Principles
We’ll Go First
Glaukos is committed to investing in the future of ophthalmology to transform standards of care and improve patient lives
Investing In Transformative Innovation
We invest a significant and peer-leading portion of our revenues in R&D to:
- Address unmet patient needs
- Deliver innovation that challenges conventional treatment paradigms
- Advance standards of care
- Improve patient lives
- Create entirely new commercial and clinical marketplaces
Our R&D investments reflect a long-term commitment to pursuing innovation in often-complex and rare disease areas, with significant risk of failure and expense before we ultimately succeed
Establishing Responsible Pricing
Glaukos thoughtfully determines pricing of our products, taking into consideration:
- Benefits and costs/cost savings to patients and health care systems
- Improvement in patients’ clinical outcomes and quality of life
- Ability to provide eligible patients in need access to our therapies
- Investment required to bring our products to market, including pioneering new markets, and to continue pursuing breakthrough innovation for the future
Our Strategy for Long-Term Growth
Our five key dropless technology therapy platforms are designed to disrupt traditional treatment paradigms and generate a robust cadence of new product introductions over the coming years that can drive long-term sustainable future growth. These platforms embody ambitious, big ideas aimed at addressing large and chronically underserved eye diseases.
Pipeline Currently Includes 14 Candidates, Plus Additional Undisclosed Programs
| Product/Candidate | Indication | U.S. Status | ||||||
|---|---|---|---|---|---|---|---|---|
| Product/CandidateiStent / iStent inject / iStent inject W | IndicationMild-to-moderate primary open-angle glaucoma in combination with cataract surgery | U.S. StatusApproved | ||||||
| Product/CandidateiAccess | IndicationManual cutting of TM during ophthalmic surgery | U.S. StatusApproved | ||||||
| Product/CandidateiStent infinite | IndicationGlaucoma (failed on prior medical and surgical therapy) Standalone | U.S. StatusApproved | ||||||
| Product/CandidateiStent infinite | IndicationEarlier Intervention Glaucoma Standalone | U.S. StatusPhase 3 | ||||||
| Product/CandidatePRESERFLO MicroShunt | IndicationGlaucoma Standalone | U.S. StatusPMA non-approvable; review ongoing | ||||||
| Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | FDA Submission | Approved | |||
| Product/Candidate | Indication | U.S. Status | ||||||
|---|---|---|---|---|---|---|---|---|
| Product/CandidateiDose TR | IndicationOcular Hypertension - Refractory Glaucoma | U.S. StatusApproved | ||||||
| Product/CandidateiDose TREX | IndicationOcular Hypertension - Refractory Glaucoma | U.S. StatusPhase 2/3 | ||||||
| Product/CandidateiDose Next-Generation | IndicationOcular Hypertension - Refractory Glaucoma | U.S. StatusPre-clinical | ||||||
| Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | FDA Submission | Approved | |||
| Product/Candidate | Indication | U.S. Status | ||||||
|---|---|---|---|---|---|---|---|---|
| Product/CandidateGLK-301 | IndicationDry Eye Disease | U.S. StatusPhase 2 | ||||||
| Product/CandidateGLK-302 | IndicationPresbyopia | U.S. StatusPhase 2 | ||||||
| Product/CandidateGLK-311 | IndicationGlaucoma | U.S. StatusPhase 2 | ||||||
| Product/CandidateGLK-311 | IndicationBlepharitis | U.S. StatusPre-clinical | ||||||
| Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | FDA Submission | Approved | |||
| Product/Candidate | Indication | U.S. Status | ||||||
|---|---|---|---|---|---|---|---|---|
| Product/CandidatePhotrexa (Epi-off) | IndicationKeratoconus | U.S. StatusApproved | ||||||
| Product/CandidateEpioxa (Epi-on) | IndicationKeratoconus | U.S. StatusFDA Submission | ||||||
| Product/CandidateThird-Generation | IndicationKeratoconus | U.S. StatusPhase 2 | ||||||
| Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | FDA Submission | Approved | |||
| Product/Candidate | Indication | U.S. Status | ||||||
|---|---|---|---|---|---|---|---|---|
| Product/CandidateGLK-401 (IVT Multi-Kinase Inhibitor) | IndicationAge-Related Macular Degeneration (AMD) Diabetic Macular Edema (DME) | U.S. StatusPhase 2 | ||||||
| Product/CandidateGLK-411 (IVT NCE Conjugate) | IndicationDME | U.S. StatusPre-clinical | ||||||
| Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | FDA Submission | Approved | |||